Trials / Completed
CompletedNCT02719028
Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
A Prospective, Double Blind, Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Golden Biotechnology Corporation · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Identified the efficacy of Antroquinonol (Hocena 50mg) in triglyceride, lipid-lowering and fatty liver.
Detailed description
The primary efficacy objective is to demonstrate the reduction of triglyceride (TG) by Antroquinonol, in comparison with placebo, after 12 weeks of treatment in patients with hypercholesterolemia and hyperlipidemia. Secondary objectives include the evaluation of the effects of Antroquinonol in comparison with placebo on other lipid parameters after 12 weeks of treatment and the effects of Antroquinonol on left ventricular diastolic function, arterial stiffness and fatty liver. The safety and tolerability of Antroquinonol will be monitored as well.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antroquinonol | Antroquinonol will be provided as capsules of 50 mg |
| DRUG | placebo | The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol) |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2018-09-27
- Completion
- 2019-03-31
- First posted
- 2016-03-25
- Last updated
- 2020-01-02
- Results posted
- 2019-12-20
Locations
6 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02719028. Inclusion in this directory is not an endorsement.